Wedbush Sticks to Its Buy Rating for Rani Therapeutics Holdings (RANI)

Wedbush analyst Andreas Argyrides reiterated a Buy rating on Rani Therapeutics Holdings (RANIResearch Report) today and set a price target of $17.00. The company’s shares closed yesterday at $8.23.

According to TipRanks, Argyrides is an analyst with an average return of -1.0% and a 30.77% success rate. Argyrides covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Global Blood Therapeutics, and Sangamo Biosciences.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Rani Therapeutics Holdings with a $19.50 average price target.

See today’s best-performing stocks on TipRanks >>

RANI market cap is currently $404.5M and has a P/E ratio of -8.02.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Rani Therapeutics Holdings Inc is a clinical stage biotherapeutics company advancing technologies to enable the development of orally administered biologics. It has developed the RaniPill capsule, proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing.

Read More on RANI:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed